Cardiac retransplantation in high risk pediatric patients

Marc E. Richmond, Linda J. Addonizio, Daphne T. Hsu, Seema R. Mital, Ralph S. Mosca, Jan M. Quaegebeur, Jonathan Chen, Jacqueline M. Lamour

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cardiac retransplantation is often the only therapy to treat GV or other causes of allograft failure. Previous reports of retransplantation have conflicting results. In this series of 18 re-transplants in 16 patients from 1984-2005, indications for retransplantation were: GV (67%); GV with cellular rejection (28%); acute graft failure (2.5%); and chronic graft failure (2.5%). Mean age at retransplantation was 12.3 (range: 0.7-22) years with a mean primary graft survival of 5.3 years (range: 8 days-10.5 years). There was no short-term mortality with only three deaths at 4, 10, and 16 years post-retransplantation. Fourteen of 18 patients had risk factors for adverse outcomes following retransplantation: ECMO support in one patient prior to retransplantation; impaired renal function in three patients; elevated panel reactive antibody screen in seven patients; a history of PTLD in five patients; and a recent episode of rejection (13-36 days) in four patients. One-, five- and ten-year survival after retransplantation was 100%, 83% and 66%, respectively, comparable to survival after primary transplantation. Freedom from rejection was not significantly different between primary and retransplantations. All patients who underwent treatment for PTLD had excellent results after retransplantation with one recurrence 16 months after retransplant. Overall, patients had excellent survival after retransplantation even in those with risk factors for poor outcome.

Original languageEnglish (US)
Pages (from-to)615-623
Number of pages9
JournalPediatric Transplantation
Volume11
Issue number6
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Pediatrics
Transplants
Survival
Graft Survival
Allografts
Transplantation
Kidney
Recurrence
Mortality
Antibodies
Therapeutics

Keywords

  • Child, survival analysis
  • Coronary disease
  • Graft rejection
  • Graft survival
  • Heart transplantation
  • Reoperation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Richmond, M. E., Addonizio, L. J., Hsu, D. T., Mital, S. R., Mosca, R. S., Quaegebeur, J. M., ... Lamour, J. M. (2007). Cardiac retransplantation in high risk pediatric patients. Pediatric Transplantation, 11(6), 615-623. https://doi.org/10.1111/j.1399-3046.2007.00698.x

Cardiac retransplantation in high risk pediatric patients. / Richmond, Marc E.; Addonizio, Linda J.; Hsu, Daphne T.; Mital, Seema R.; Mosca, Ralph S.; Quaegebeur, Jan M.; Chen, Jonathan; Lamour, Jacqueline M.

In: Pediatric Transplantation, Vol. 11, No. 6, 09.2007, p. 615-623.

Research output: Contribution to journalArticle

Richmond, ME, Addonizio, LJ, Hsu, DT, Mital, SR, Mosca, RS, Quaegebeur, JM, Chen, J & Lamour, JM 2007, 'Cardiac retransplantation in high risk pediatric patients', Pediatric Transplantation, vol. 11, no. 6, pp. 615-623. https://doi.org/10.1111/j.1399-3046.2007.00698.x
Richmond ME, Addonizio LJ, Hsu DT, Mital SR, Mosca RS, Quaegebeur JM et al. Cardiac retransplantation in high risk pediatric patients. Pediatric Transplantation. 2007 Sep;11(6):615-623. https://doi.org/10.1111/j.1399-3046.2007.00698.x
Richmond, Marc E. ; Addonizio, Linda J. ; Hsu, Daphne T. ; Mital, Seema R. ; Mosca, Ralph S. ; Quaegebeur, Jan M. ; Chen, Jonathan ; Lamour, Jacqueline M. / Cardiac retransplantation in high risk pediatric patients. In: Pediatric Transplantation. 2007 ; Vol. 11, No. 6. pp. 615-623.
@article{24299a5c450249f3b5aca7405b16667e,
title = "Cardiac retransplantation in high risk pediatric patients",
abstract = "Cardiac retransplantation is often the only therapy to treat GV or other causes of allograft failure. Previous reports of retransplantation have conflicting results. In this series of 18 re-transplants in 16 patients from 1984-2005, indications for retransplantation were: GV (67{\%}); GV with cellular rejection (28{\%}); acute graft failure (2.5{\%}); and chronic graft failure (2.5{\%}). Mean age at retransplantation was 12.3 (range: 0.7-22) years with a mean primary graft survival of 5.3 years (range: 8 days-10.5 years). There was no short-term mortality with only three deaths at 4, 10, and 16 years post-retransplantation. Fourteen of 18 patients had risk factors for adverse outcomes following retransplantation: ECMO support in one patient prior to retransplantation; impaired renal function in three patients; elevated panel reactive antibody screen in seven patients; a history of PTLD in five patients; and a recent episode of rejection (13-36 days) in four patients. One-, five- and ten-year survival after retransplantation was 100{\%}, 83{\%} and 66{\%}, respectively, comparable to survival after primary transplantation. Freedom from rejection was not significantly different between primary and retransplantations. All patients who underwent treatment for PTLD had excellent results after retransplantation with one recurrence 16 months after retransplant. Overall, patients had excellent survival after retransplantation even in those with risk factors for poor outcome.",
keywords = "Child, survival analysis, Coronary disease, Graft rejection, Graft survival, Heart transplantation, Reoperation",
author = "Richmond, {Marc E.} and Addonizio, {Linda J.} and Hsu, {Daphne T.} and Mital, {Seema R.} and Mosca, {Ralph S.} and Quaegebeur, {Jan M.} and Jonathan Chen and Lamour, {Jacqueline M.}",
year = "2007",
month = "9",
doi = "10.1111/j.1399-3046.2007.00698.x",
language = "English (US)",
volume = "11",
pages = "615--623",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Cardiac retransplantation in high risk pediatric patients

AU - Richmond, Marc E.

AU - Addonizio, Linda J.

AU - Hsu, Daphne T.

AU - Mital, Seema R.

AU - Mosca, Ralph S.

AU - Quaegebeur, Jan M.

AU - Chen, Jonathan

AU - Lamour, Jacqueline M.

PY - 2007/9

Y1 - 2007/9

N2 - Cardiac retransplantation is often the only therapy to treat GV or other causes of allograft failure. Previous reports of retransplantation have conflicting results. In this series of 18 re-transplants in 16 patients from 1984-2005, indications for retransplantation were: GV (67%); GV with cellular rejection (28%); acute graft failure (2.5%); and chronic graft failure (2.5%). Mean age at retransplantation was 12.3 (range: 0.7-22) years with a mean primary graft survival of 5.3 years (range: 8 days-10.5 years). There was no short-term mortality with only three deaths at 4, 10, and 16 years post-retransplantation. Fourteen of 18 patients had risk factors for adverse outcomes following retransplantation: ECMO support in one patient prior to retransplantation; impaired renal function in three patients; elevated panel reactive antibody screen in seven patients; a history of PTLD in five patients; and a recent episode of rejection (13-36 days) in four patients. One-, five- and ten-year survival after retransplantation was 100%, 83% and 66%, respectively, comparable to survival after primary transplantation. Freedom from rejection was not significantly different between primary and retransplantations. All patients who underwent treatment for PTLD had excellent results after retransplantation with one recurrence 16 months after retransplant. Overall, patients had excellent survival after retransplantation even in those with risk factors for poor outcome.

AB - Cardiac retransplantation is often the only therapy to treat GV or other causes of allograft failure. Previous reports of retransplantation have conflicting results. In this series of 18 re-transplants in 16 patients from 1984-2005, indications for retransplantation were: GV (67%); GV with cellular rejection (28%); acute graft failure (2.5%); and chronic graft failure (2.5%). Mean age at retransplantation was 12.3 (range: 0.7-22) years with a mean primary graft survival of 5.3 years (range: 8 days-10.5 years). There was no short-term mortality with only three deaths at 4, 10, and 16 years post-retransplantation. Fourteen of 18 patients had risk factors for adverse outcomes following retransplantation: ECMO support in one patient prior to retransplantation; impaired renal function in three patients; elevated panel reactive antibody screen in seven patients; a history of PTLD in five patients; and a recent episode of rejection (13-36 days) in four patients. One-, five- and ten-year survival after retransplantation was 100%, 83% and 66%, respectively, comparable to survival after primary transplantation. Freedom from rejection was not significantly different between primary and retransplantations. All patients who underwent treatment for PTLD had excellent results after retransplantation with one recurrence 16 months after retransplant. Overall, patients had excellent survival after retransplantation even in those with risk factors for poor outcome.

KW - Child, survival analysis

KW - Coronary disease

KW - Graft rejection

KW - Graft survival

KW - Heart transplantation

KW - Reoperation

UR - http://www.scopus.com/inward/record.url?scp=34547454749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547454749&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2007.00698.x

DO - 10.1111/j.1399-3046.2007.00698.x

M3 - Article

C2 - 17663683

AN - SCOPUS:34547454749

VL - 11

SP - 615

EP - 623

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 6

ER -